Search hospitals > Nevada > Las Vegas

GenesisCare USA - Las Vegas

Claim this profile
Las Vegas, Nevada 89109
Global Leader in Cancer
Global Leader in Adenocarcinoma
Conducts research for Tumors
Conducts research for Breast Cancer
Conducts research for Lung Cancer
116 reported clinical trials
2 medical researchers
Photo of GenesisCare USA - Las Vegas in Las VegasPhoto of GenesisCare USA - Las Vegas in Las VegasPhoto of GenesisCare USA - Las Vegas in Las Vegas

Summary

GenesisCare USA - Las Vegas is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Adenocarcinoma, Tumors, Breast Cancer, Lung Cancer and other specialties. GenesisCare USA - Las Vegas is involved with conducting 116 clinical trials across 320 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.

Area of expertise

1Cancer
Global Leader
GenesisCare USA - Las Vegas has run 45 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Adenocarcinoma
Global Leader
GenesisCare USA - Las Vegas has run 18 trials for Adenocarcinoma. Some of their research focus areas include:
Stage IV
Stage II
Stage III

Top PIs

Clinical Trials running at GenesisCare USA - Las Vegas

Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Lung Cancer
Prostate Cancer
Cancer
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Image of trial facility.

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Symptom Monitoring

for Young Women on Hormone Therapy

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Image of trial facility.

Mobile Health

for Breast Cancer

This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at GenesisCare USA - Las Vegas?
GenesisCare USA - Las Vegas is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Adenocarcinoma, Tumors, Breast Cancer, Lung Cancer and other specialties. GenesisCare USA - Las Vegas is involved with conducting 116 clinical trials across 320 conditions. There are 2 research doctors associated with this hospital, such as John A. Ellerton and Alan K. Ikeda.